ArticleBlood2019
Lack of
Open access · bronzeAbstract readLetter
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- The use of luspatercept for thalassemia in adults.Blood advances · 2021Trial
- Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP-SMAD Signaling to Therapeutic Modulation.Biomolecules · 2026Review
- Luspatercept: From Bench to Bedside and Beyond in the Management of Ineffective Erythropoiesis.Journal of hematology · 2026Review
- Clinical Applications of Ligand Traps Targeting Activin Type II Receptors.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026Review
- TNFα signaling restores steady-state hematopoiesis in a TNFαKO mouse model of anemia of inflammation.Blood · 2025Article
- Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control.Scientific reports · 2025Article
- Iron-Loading Anemias.Advances in experimental medicine and biology · 2025Review
- Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.American journal of hematology · 2024Article
- Tissue Expression of Growth Differentiation Factor 11 in Patients with Breast Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches.Frontiers in oncology · 2024Review
- Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis.Haematologica · 2023Review
- An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertension.Developmental dynamics : an official publication of the American Association of Anatomists · 2023Review
- Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.Drug design, development and therapy · 2023Review
- Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice.Leukemia · 2022Article
- Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis.Diseases (Basel, Switzerland) · 2022Review
- SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.Clinical lymphoma, myeloma & leukemia · 2021Review
- The Role of Iron in Benign and Malignant Hematopoiesis.Antioxidants & redox signaling · 2021Review
- Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.International journal of molecular sciences · 2021Review
- EnvIRONmental Aspects in Myelodysplastic Syndrome.International journal of molecular sciences · 2021Review
- The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance.International journal of molecular sciences · 2021Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 3 institutions in 2 countries.
Amaliris GuerraDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0002-6602-1854
Paraskevi Rea OikonomidouDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Sayantani SinhaDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Jianbing ZhangDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Vania Lo PrestiDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Callum R HamiltonDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Laura BredaDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Carla CasuDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Ping LaDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Ana C MartinsChronic Diseases Research Center, NOVA Medical School, NOVA University of Lisbon, Lisbon, Portugal; and.
Anoop K SendamaraiDepartment of Pathology, Boston Children's Hospital, Boston, MA.
Mark FlemingDepartment of Pathology, Boston Children's Hospital, Boston, MA.
Stefano RivellaDivision of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0002-0938-6558
Children's Hospital of Philadelphia · USBoston Children's Hospital · USUniversity of Lisbon · PT
Funding
HEMATOLOGY CLINICAL RESEARCH TRAINING PROGRAMT32HL007439 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE F BRASS, PETER S KLEIN · 1985 to 2026
$17.1MRegulatory Role of Transferrin in Erythropoiesis and Iron MetabolismR01DK095112 · NIDDK · SAINT LOUIS UNIVERSITY · PI Robert E Fleming, Yelena Ginzburg · 2012 to 2026
$5.4MHepcidin therapy for iron overload and hematologic disordersR01DK090554 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI RIVELLA, STEFANO · 2010 to 2021
$5.2MNHLBI NIH HHS T32 HL007439NIDDK NIH HHS R01 DK090554NIDDK NIH HHS R01 DK095112
Abstract
PubMed holds no abstract for this paper.
Indexed as
beta-ThalassemiaBone Morphogenetic ProteinsGrowth Differentiation FactorsRecombinant Fusion ProteinsActivin Receptors, Type IIAnemiaAnimalsBiomarkersDisease Models, AnimalImmunoglobulin Fc FragmentsMiceMice, TransgenicTreatment OutcomeActivin Receptors, Type IIBiomarkersBone Morphogenetic ProteinsGdf11 protein, mouseGrowth Differentiation FactorsImmunoglobulin Fc FragmentsluspaterceptRecombinant Fusion Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.